FDA Grants Accelerated Approval to the Combination of Avutometinib and Defactinib for KRAS-mutated Recurrent Low-Grade Serous Ovarian Cancer By Ogkologos - May 30, 2025 717 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the RAMP-201 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Granting a Marketing Authorisation for Generic Palbociclib Metastasis-Directed Therapy for Oligometastatic Solid Tumours in Histology-Specific Context ctDNA Testing After Neoadjuvant Chemotherapy and Radical Cystectomy Predicts Recurrence Risk in Patients with MIBC MOST POPULAR Chemotherapy Administered for the First Diagnosed Testicular Cancer Reduces the Risk... January 13, 2021 Immunotherapy is Beneficial in Gastric and Oesophageal Cancers, Studies Show [ESMO2020... September 21, 2020 Mom Births Stillborn Baby But Never Anticipated Nurse’s Remark She Will... March 15, 2019 Multipronged Approach Eliminates Racial Disparities in Early-Stage Lung Cancer Treatment March 5, 2019 Load more HOT NEWS Neoadjuvant Ipilimumab Plus Nivolumab Results in Longer EFS Than Adjuvant Nivolumab... Science Surgery: ‘Can cancers develop in the heart?’ Enhertu May Be Preferred Therapy for Some Metastatic Breast Cancers Study in India Could Make Immunotherapy More Affordable Worldwide
